LIMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Liminatus Pharma Inc (LIMN) is not a good buy for a beginner, long-term investor at this time. The stock demonstrates weak technical indicators, no positive trading trends, and lacks significant catalysts or growth in financial performance. Additionally, there are no proprietary trading signals suggesting a strong buy opportunity.
The stock shows bearish technical indicators with MACD below 0 (-0.067) and negatively contracting, RSI at 26.631 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 0.21, and resistance is at 0.561, indicating limited upward momentum.
NULL identified. No recent news, trading trends, or significant financial improvements.
The stock's regular market change is -3.77%, and financial performance shows no revenue growth. Insider and hedge fund activity are neutral, and technical indicators are bearish.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -1,823,351 (up 202.98% YoY), and an EPS of -0.07 (up 250% YoY). Gross margin remains at 0, showing no profitability.
No data available for analyst ratings or price target changes.
